Amendments to the Claims:

Pursuant to 37 C.F.R. §1.121(c), this listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Original) A method of treating a subject afflicted with a form of multiple sclerosis comprising periodically administering to the subject an amount of glatiramer acetate and an amount of mitoxantrone, wherein the amounts when taken together are effective to alleviate a symptom of the form of multiple sclerosis in the subject so as to thereby treat the subject.

2. (Original) The method of claim 1, wherein the form of multiple sclerosis is relapsing-remitting multiple sclerosis.

3. (Previously Presented) The method of claim 1, wherein the subject is a human being.

4. (Previously Presented) The method of claim 1, wherein each of the amount of glatiramer acetate when taken alone, and the amount of mitoxantrone when taken alone is effective to alleviate the symptom of the form of multiple sclerosis.

5. (Previously Presented) The method of claim 1, wherein either the amount of glatiramer acetate when taken alone, the amount of mitoxantrone when taken alone or each such amount when taken alone is not effective to alleviate the symptom of the form of multiple sclerosis.

6. (Previously Presented) The method of claim 1, wherein the

symptom is the frequency of relapses, the frequency of clinical exacerbation, or the accumulation of physical disability.

7. (Previously Presented) The method of claim 1, wherein the amount of glatiramer acetate is in the range from 10 to 600 mg/week.

8. (Original) The method of claim 7, wherein the amount of glatiramer acetate is 300 mg/week.

9. (Previously Presented) The method of claim 1, wherein the amount of glatiramer acetate is in the range from 50 to 150 mg/day.

10. (Original) The method of claim 9, wherein the amount of glatiramer acetate is 100 mg/day.

11. (Previously Presented) The method of claim 1, wherein the amount of glatiramer acetate is in the range from 10 to 80 mg/day.

12. (Original) The method of claim 11, wherein the amount of glatiramer acetate is 20 mg/day.

13. (Previously Presented) The method of claim 1, wherein the periodic administration of glatiramer acetate is effected daily.

14. (Previously Presented) The method of claim 1, wherein the periodic administration of glatiramer acetate is effected twice daily at one half the amount.

15. (Previously Presented) The method of claim 1, wherein the

periodic administration of glatiramer acetate is effected once every 5 to 9 days.

16. (Previously Presented) The method of claim 1, wherein the administration of the glatiramer acetate substantially precedes the administration of the mitoxantrone.

17. (Previously Presented) The method of claim 1, wherein the administration of the mitoxantrone substantially precedes the administration of the glatiramer acetate.

18. (Previously Presented) The method of claim 1, wherein the administration of the glatiramer acetate is effected subcutaneously, intraperitoneally, intravenously, intramuscularly, intraocularly or orally and the administration of the mitoxantrone is effected intravenously.

19. (Original) The method of claim 18, wherein the administration of the glatiramer acetate is effected subcutaneously and the administration of the mitoxantrone is effected intravenously.

20. (Original) A pharmaceutical composition comprising an amount of glatiramer acetate and an amount of mitoxantrone, wherein the amounts when taken together are effective to alleviate a symptom of a form of multiple sclerosis in a subject.

21. (Original) The pharmaceutical composition of claim 20, wherein each of the amount of glatiramer acetate when taken alone and the amount of mitoxantrone when taken alone is effective to alleviate the symptom of multiple sclerosis.

22. (Original) The pharmaceutical composition of claim 20, wherein either of the amount of glatiramer acetate when taken alone, or the amount of mitoxantrone when taken alone or each such

amount when taken alone is not effective to alleviate the symptom of multiple sclerosis.

23. (Original) A package comprising

a first pharmaceutical composition comprising an amount of glatiramer acetate and a pharmaceutically acceptable carrier;

a second pharmaceutical composition comprising an amount of mitoxantrone and a pharmaceutically acceptable carrier; and

instructions for use of the first and second pharmaceutical compositions together to alleviate a symptom of a form of multiple sclerosis in a subject.

24. (Original) The package of claim 23, wherein the amount of glatiramer acetate is 300 mg.

25. (Original) The package of claim 23, wherein the amount of glatiramer acetate is 20 mg.

26. (New) The method of claim 1 wherein the effect on the subject is greater than the effect on a subject treated with glatiramer acetate alone.

27. (New) The method of claim 26 wherein the reduction of the accumulation of Gd-enhancing lesions in the subject is greater than the reduction of the accumulation of Gd-enhancing lesions in a subject treated with glatiramer acetate alone.

28. (New) The method of claim 26 wherein the reduction in relapse rate in the subject is greater than the reduction in relapse rate in a subject treated with glatiramer acetate alone.

29. (New) The method of claim 4 wherein the efficacy of glatiramer acetate is enhanced.